Spruce Biosciences (SPRB) Common Equity (2019 - 2026)
Spruce Biosciences (SPRB) posted quarterly Common Equity of $34.6 million for Q1 2026, up 126.1% year-over-year from $15.3 million in Q1 2025, and down 18.51% quarter-over-quarter from $42.5 million in Q4 2025.
Spruce Biosciences (SPRB) Common Equity (2019 - 2026) Analysis & Trends
Spruce Biosciences (SPRB) has reported Common Equity for 8 consecutive years, with $34.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity rose 126.1% year-over-year to $34.6 million; the TTM figure through Mar 2026 stood at $34.6 million (up 126.1% YoY), while the FY2025 annual figure was $42.5 million, up 47.52% from the prior year.
- Common Equity eased to $34.6 million in Q1 2026 per SPRB's latest filing, from $42.5 million in the prior quarter.
- Across five years, Common Equity topped out at $108.0 million in Q1 2023 and bottomed at $5.4 million in Q3 2025.
- Historically, Common Equity has averaged $60.0 million across 5 years, with a median of $66.6 million in 2024.
- Annual changes were most pronounced in 2025 — Common Equity sank 89.57% — and 2026, when it soared 126.1%.
- Spruce Biosciences' Common Equity stood at $68.5 million in 2022, then gained by 11.71% to $76.5 million in 2023, then slumped by 62.33% to $28.8 million in 2024, then surged by 47.52% to $42.5 million in 2025, then fell by 18.51% to $34.6 million in 2026.
- Business Quant data shows SPRB's Common Equity at $34.6 million in Q1 2026, $42.5 million in Q4 2025, and $5.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | Spruce Biosciences | 119.20 Mn | 119.20 Mn | - | 83.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 83.73 Mn |
| Mar 31, 2026 | 34.65 Mn |
| Dec 31, 2025 | 42.52 Mn |
| Sep 30, 2025 | 5.39 Mn |
| Jun 30, 2025 | 13.18 Mn |
| Mar 31, 2025 | 15.32 Mn |
| Dec 31, 2024 | 28.82 Mn |
| Sep 30, 2024 | 51.64 Mn |
| Jun 30, 2024 | 59.17 Mn |
| Mar 31, 2024 | 66.62 Mn |
| Dec 31, 2023 | 76.51 Mn |
| Sep 30, 2023 | 85.38 Mn |
| Jun 30, 2023 | 96.56 Mn |
| Mar 31, 2023 | 108.00 Mn |
| Dec 31, 2022 | 68.49 Mn |
| Sep 30, 2022 | 78.48 Mn |
| Jun 30, 2022 | 89.12 Mn |
| Mar 31, 2022 | 100.24 Mn |
| Dec 31, 2021 | 111.37 Mn |
| Sep 30, 2021 | 119.72 Mn |